1073 related articles for article (PubMed ID: 27144536)
1. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Li H; Zhu Y; Burnside ES; Drukker K; Hoadley KA; Fan C; Conzen SD; Whitman GJ; Sutton EJ; Net JM; Ganott M; Huang E; Morris EA; Perou CM; Ji Y; Giger ML
Radiology; 2016 Nov; 281(2):382-391. PubMed ID: 27144536
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.
Sutton EJ; Oh JH; Dashevsky BZ; Veeraraghavan H; Apte AP; Thakur SB; Deasy JO; Morris EA
J Magn Reson Imaging; 2015 Nov; 42(5):1398-406. PubMed ID: 25850931
[TBL] [Abstract][Full Text] [Related]
3. Qualitative Radiogenomics: Association between Oncotype DX Test Recurrence Score and BI-RADS Mammographic and Breast MR Imaging Features.
Woodard GA; Ray KM; Joe BN; Price ER
Radiology; 2018 Jan; 286(1):60-70. PubMed ID: 28885890
[TBL] [Abstract][Full Text] [Related]
4. Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers: Preliminary results for correlation with Oncotype DX recurrence scores.
Nam KJ; Park H; Ko ES; Lim Y; Cho HH; Lee JE
Medicine (Baltimore); 2019 Jun; 98(23):e15871. PubMed ID: 31169691
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Low versus High Recurrence Scores in Estrogen Receptor-Positive, Lymph Node-Negative Invasive Breast Cancer on the Basis of Radiologic-Pathologic Features: Comparison with Oncotype DX Test Recurrence Scores.
Dialani V; Gaur S; Mehta TS; Venkataraman S; Fein-Zachary V; Phillips J; Brook A; Slanetz PJ
Radiology; 2016 Aug; 280(2):370-8. PubMed ID: 26937802
[TBL] [Abstract][Full Text] [Related]
6. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
7. Radiogenomic Signatures of Oncotype DX Recurrence Score Enable Prediction of Survival in Estrogen Receptor-Positive Breast Cancer: A Multicohort Study.
Fan M; Cui Y; You C; Liu L; Gu Y; Peng W; Bai Q; Gao X; Li L
Radiology; 2022 Mar; 302(3):516-524. PubMed ID: 34846204
[TBL] [Abstract][Full Text] [Related]
8. Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles.
Ashraf AB; Daye D; Gavenonis S; Mies C; Feldman M; Rosen M; Kontos D
Radiology; 2014 Aug; 272(2):374-84. PubMed ID: 24702725
[TBL] [Abstract][Full Text] [Related]
9. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric MR Imaging Radiomics Signatures for Assessing the Recurrence Risk of ER+/HER2- Breast Cancer Quantified With 21-Gene Recurrence Score.
Chen Y; Tang W; Liu W; Li R; Wang Q; Shen X; Gong J; Gu Y; Peng W
J Magn Reson Imaging; 2023 Aug; 58(2):444-453. PubMed ID: 36440706
[TBL] [Abstract][Full Text] [Related]
11. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
12. Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.
Gyanchandani R; Lin Y; Lin HM; Cooper K; Normolle DP; Brufsky A; Fastuca M; Crosson W; Oesterreich S; Davidson NE; Bhargava R; Dabbs DJ; Lee AV
Clin Cancer Res; 2016 Nov; 22(21):5362-5369. PubMed ID: 27185370
[TBL] [Abstract][Full Text] [Related]
13. Mammography-based radiomics for predicting the risk of breast cancer recurrence: a multicenter study.
Mao N; Yin P; Zhang H; Zhang K; Song X; Xing D; Chu T
Br J Radiol; 2021 Nov; 94(1127):20210348. PubMed ID: 34520235
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment MR imaging radiomics signatures for response prediction to induction chemotherapy in patients with nasopharyngeal carcinoma.
Wang G; He L; Yuan C; Huang Y; Liu Z; Liang C
Eur J Radiol; 2018 Jan; 98():100-106. PubMed ID: 29279146
[TBL] [Abstract][Full Text] [Related]
15. Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging.
Mazurowski MA; Zhang J; Grimm LJ; Yoon SC; Silber JI
Radiology; 2014 Nov; 273(2):365-72. PubMed ID: 25028781
[TBL] [Abstract][Full Text] [Related]
16. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
Kelly CM; Bernard PS; Krishnamurthy S; Wang B; Ebbert MT; Bastien RR; Boucher KM; Young E; Iwamoto T; Pusztai L
Oncologist; 2012; 17(4):492-8. PubMed ID: 22418568
[TBL] [Abstract][Full Text] [Related]
17. Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.
Kim HJ; Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
Clin Imaging; 2021 Jul; 75():131-137. PubMed ID: 33548871
[TBL] [Abstract][Full Text] [Related]
18. Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.
Ha R; Chang P; Mutasa S; Karcich J; Goodman S; Blum E; Kalinsky K; Liu MZ; Jambawalikar S
J Magn Reson Imaging; 2019 Feb; 49(2):518-524. PubMed ID: 30129697
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer.
Wu J; Li B; Sun X; Cao G; Rubin DL; Napel S; Ikeda DM; Kurian AW; Li R
Radiology; 2017 Nov; 285(2):401-413. PubMed ID: 28708462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
